PhaseBio Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2021	2020	2019	2018	2017	2016
Cash & Equivalents	41.8	28.12	74.03	61.03	13.41	3.72
Cash & Cash Equivalents	41.8	28.12	74.03	61.03	13.41	3.72
Cash Growth	48.64%	-62.01%	21.29%	355.25%	260.86%	-
Receivables	0	0	1.23	0.23	0	0
Other Current Assets	6.98	12.03	3.57	1.36	0.34	0.17
Total Current Assets	48.78	40.15	78.82	62.63	13.75	3.88
Property, Plant & Equipment	11.7	10.15	3.64	0.36	0.3	0.18
Other Long-Term Assets	0.06	0.06	0.03	0.04	0.05	0.05
Total Long-Term Assets	11.76	10.21	3.67	0.4	0.35	0.23
Total Assets	60.54	50.36	82.49	63.03	14.1	4.12
Accounts Payable	12.57	3.67	2.92	1.81	0.43	0.43
Deferred Revenue	1.55	0	0	0	0	0
Current Debt	5.41	5.36	2.38	0	0	0
Other Current Liabilities	8.35	5.93	3.18	2.77	17.17	0.41
Total Current Liabilities	27.88	14.96	8.48	4.58	17.6	0.84
Long-Term Debt	2.43	6.77	12.33	7.5	2.63	0
Other Long-Term Liabilities	123.26	53.83	1.71	0.02	91.3	90.46
Total Long-Term Liabilities	125.69	60.6	14.04	7.52	93.92	90.46
Total Liabilities	153.57	75.56	22.52	12.1	111.52	91.3
Total Debt	7.85	12.13	14.7	7.5	15.48	0
Debt Growth	-35.31%	-17.52%	96.05%	-51.55%	-	-
Common Stock	0.05	0.03	0.03	0.03	0	0
Retained Earnings	-391.79	-260.72	-162.16	-122.91	-99.07	-88.82
Comprehensive Income	0	0	-1.96	-1.79	-1.65	-1.55
Shareholders' Equity	-93.03	-25.2	59.98	50.93	-97.42	-87.18
Total Liabilities and Equity	60.54	50.36	82.49	63.03	14.1	4.12
Net Cash / Debt	33.96	15.99	59.32	53.53	-2.08	3.72
Net Cash / Debt Growth	112.30%	-73.04%	10.82%	-	-	-
Net Cash Per Share	1.16	0.55	2.16	10.09	-0.18	0.30
Working Capital	20.9	25.19	70.34	58.05	-3.85	3.04
Book Value Per Share	-3.16	-0.87	2.18	9.60	-8.66	-7.04

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.